“This will change surgery forever” was the general sentiment from a University of Washington commissioned survey of applicable surgeons.

Over the last 9 years, the Novuson founders have established scientific credibility via compelling proof of concept trials. We are now transitioning from an R&D company to a manufacturing and marketing company, delivering product systems at a national then global scale.

Our technology’s performance has been solidly demonstrated, both in ex vivo tissue samples and in vivo swine trials. Now we need to invest in product development, manufacturing, and 510k FDA clearance, as well as fill out our technical and management teams with proven producers.

A highly regarded FDA consulting firm in Washington (Drug and Device Development) has issued a Position Letter indicating our FDA classification to be 510K.

We hold 4 granted US utility patents and 4 pending utility patents.  Novuson owns worldwide exclusive license to these patents.

We have received support from a number of organizations:

Madigan Military Medical Center (Joint Base Fort Lewis/McChord) invited us to join them in a Cooperative Research and Development Agreement (CRADA), in which Madigan would conduct our human subjects trials at no cost to Novuson.

National Institute of Health (NIH) has awarded us multiple grants: Phase 1 STTR grant of $225K completed with a Perfect Score. $1.5M in March of 2016 for a Direct to Phase II through NIGMS (Hemostatic Clamp), and an additional $1.5M in September of 2016 through NHLBI (Perioperative Bleeding).

Our next step is to integrate the lab prototype into a product-ready clinical system suitable for 510K clearance by the FDA. We project 6 months are needed before we launch into the US general surgical market. We will first sell our system to the top general surgery hospitals in the North American market before expanding to Europe, Japan, and China where we will use local distributing partners to enter the general surgery markets.

Stuart B Mitchell, PhD, Chairman, CEO, CSO, Inventor of the Technology, Co-Founder

Over 20 years experience in biomedical instrumentation, 10 years in acoustic device and 15 years in tissue response to stimuli. Inventor of Novuson’s technology, conceptualized the market space, and developed the business strategy. Managed million dollar corporations/projects for 30 years. Started ACCES with Jean Maixner, grew to a multi-location practice with 70% CAGR, successful exit via merger with nationwide company.

Derek Khorsand, MD, Chief Medical Director

Dr. Khorsand will lead our clinical outreach, review Novuson's technology value proposition and provide feedback on technical usability. Dr. Khorsand is a Resident Physician of Interventional Radiology at the Univ. of WA Med Ctr. He did his Internship in General Surgery at Virginia Mason Med Ctr. Dr. Khorsand received his Doctor of Medicine from the Univ of WA School of Medicine and his Bachelor of Science in Biochemistry from the Univ of WA.

EVP of Operations and Finance

Dr. Maixner was the founder of Animal Critical Care and Emergency Services. She has over 25 years of emergency and critical care veterinary experience and 10 years of business management.

Marco Daoura, BSEE, MSBioE, SSGBC, EVP of Program and Product

With 22 years in healthcare, Marco’s work in innovation crosses multidisciplinary areas from technology, to services, program & product management, commercialization & marketing. He holds several health-tech patents, and has launched numerous successful life sciences products, where he optimizes development & commercialization strategies to improve patient outcomes, simplify provider workflows, and reduce provider/payor costs & waste.